The expression of tumor associated carbohydrates correlates strongly with poor survival rates of cancer patients. The differential expression of tumor-associated carbohydrates has been exploited for the development of therapeutic cancer vaccines. Several clinical trails have shown that vaccines based on a tumor associated carbohydrate conjugated to a carrier protein elicit mainly inferior IgM antibodies. To address this problem, we have designed, chemically synthesized and immunologically evaluated a number of fully synthetic cancer vaccine candidates that have the potential to reverse immunotolerance. We have identified compounds that can elicit robust humoral and cellular immune responses to tumor associated carbohydrates and are efficacious in reversing tolerance and generate a therapeutic response in a mouse model of mammary cancer.

Development of fully synthetic self-adjuvanting cancer vaccines

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.